Insight Molecular Diagnostics Inc. Foreign Currency Transaction Gain (Loss), Unrealized
Insight Molecular Diagnostics Inc. (IMDX) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$12.00K.
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was $5.00K.
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$15.00K, a 145.45% decline year-over-year.
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $18.00K.
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$185.00K, a 4725.00% decline from fiscal 2024.
- Insight Molecular Diagnostics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $4.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$7.00K 10-Q · filed 2026-08-10 | -$22.00K derived: sum of 3 quarters · filed 2026-08-10 | -$4.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-13 | -$10.00K derived: sum of 2 quarters · filed 2026-05-13 | $8.00K derived: sum of 3 quarters · filed 2026-05-13 | -$141.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.00K derived: sum of 2 quarters · filed 2026-03-26 | -$146.00K derived: sum of 3 quarters · filed 2026-08-10 | -$185.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$131.00K derived: sum of 2 quarters · filed 2026-08-10 | -$170.00K 10-Q · filed 2025-11-10 | -$137.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$149.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$188.00K 10-Q · filed 2026-08-10 | -$155.00K derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-03-31 | -$39.00K 10-Q · filed 2026-05-13 | -$6.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.00K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$29.00K 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |